Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 5/2021

01-05-2021 | Diabetic Retinopathy | Original Paper

Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy

Authors: Liting Hu, Qiulu Chen, Zhaodong Du, Wenying Wang, Guiqiu Zhao

Published in: International Ophthalmology | Issue 5/2021

Login to get access

Abstract

Background

To explore the treatment efficacy of the combination of preoperative intravitreal ranibizumab (IVR) and postoperative intravitreal triamcinolone acetonide (IVTA) in patients undergoing pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR).

Methods

A retrospective comparative study was performed on 128 eyes of 128 patients who had PDR and underwent PPV. Patients who received a single PPV were assigned to Group A. Those who received PPV with preoperative IVR were assigned to Group B. Patients in Group C underwent PPV combined preoperative IVR and postoperative IVTA. Intraoperative findings, changes in mean best-corrected visual acuity (BCVA) and postoperative adverse events, were retrospectively evaluated at 6-month follow-up.

Results

The incidences of iatrogenic breaks, severe intraoperative bleeding, using long-term internal tamponade agents, recurrent vitreous hemorrhage (VH), and duration of surgery were statistically significantly less in Group B and Group C than in Group A. The postoperative BCVA was statistically significantly better in Groups B and Group C than in Group A, respectively, at 1 month after surgery. The mean 3-month postoperative visual acuity was better in Group C. The incidence of high intraocular pressure (IOP) was significantly higher in Group C at the first postoperative week. There were no statistically significant differences in the incidence of exudative retinal detachment and choroidal detachment among the three groups.

Conclusion

In patients undergoing PPV for PDR, preoperative IVR significantly reduced the occurrence of intraoperative and postoperative complications, and the combination of preoperative IVR and postoperative IVTA can better improve the postoperative visual outcome.
Literature
1.
Fong DS, Aiello LP, Ferris FL 3rd, Klein R (2004) Diabetic retinopathy. Diabetes Care 27(10):2540–2553CrossRef
2.
Sharma T, Fong A, Lai TY, Lee V, Das S, Lam D (2016) Surgical treatment for diabetic vitreoretinal diseases: a review. Clin Exp Ophthalmol 44(4):340–354CrossRef
3.
Guan G, Zang J (2015) Meta-analysis of the effect of perioperative injection of Lucentis on intraoperative bleeding in patients with proliferative diabetic retinopathy. Eye Sci 30(4):171–175PubMed
4.
Hernandez-Da Mota SE, Nunez-Solorio SM (2010) Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol 20(6):1047–1052CrossRef
5.
Zhao LQ, Zhu H, Zhao PQ, Hu YQ (2011) A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 95(9):1216–1222CrossRef
6.
Romano V, Angi M, Scotti F, del Grosso R, Romano D, Semeraro F, Vinciguerra P, Costagliola C, Romano MR (2013) Inflammation and macular oedema after pars plana vitrectomy. Mediators Inflamm 2013:971758PubMedPubMedCentral
7.
Romero-Aroca P (2013) Current status in diabetic macular edema treatments. World J Diabetes 4(5):165–169CrossRef
8.
Nonomura S, Oshitari T, Arai M, Sato E, Takatsuna Y, Baba T, Yamamoto S (2014) The effect of posterior sub-Tenon’s capsule triamcinolone acetonide injection to that of pars plana vitrectomy for diabetic macular edema. Clin Ophthalmol 8:825–830PubMedPubMedCentral
9.
Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH (2006) Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 22(3):200–207CrossRef
10.
Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113(9):1533–1538CrossRef
11.
Lim JW, Lee HK, Shin MC (2012) Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica 227(2):100–106CrossRef
12.
Jin E, Luo L, Bai Y, Zhao M (2015) Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema. Ann Pharmacother 49(4):387–397CrossRef
13.
Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246(4):483–489CrossRef
14.
Wang YS, Li X, Wang HY, Zhang ZF, Li MH, Su XN (2011) Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Chin Med J (Engl) 124(3):352–358
15.
Kroll P, Rodrigues EB, Hoerle S (2007) Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica 221(2):78–94CrossRef
16.
Yang CM, Yeh PT, Yang CH, Chen MS (2008) Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 146(2):211–217CrossRef
17.
Sun DF, Wang YL, Wang B, Xu CL, Zhang G, Li J, Zhang XM (2019) Predictive risk factors for exudative retinal detachment after vitrectomy for proliferative diabetic retinopathy. Medicine (Baltimore) 98(8):e14603CrossRef
18.
Suzuki Y, Suzuki K, Yokoi Y, Miyagawa Y, Metoki T, Nakazawa M (2014) Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy. Retina 34(1):165–171CrossRef
19.
Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118(4):445–450CrossRef
20.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480–1487CrossRef
21.
Pe’er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72(6):638–645PubMed
22.
Cui J, Chen H, Lu H, Dong F, Wei D, Jiao Y, Charles S, Gu W, Wang L (2018) Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy. J Ophthalmol 2018:4927259PubMedPubMedCentral
23.
Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, Gregg EW, Albright AL, Klein BE, Klein R (2010) Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 304(6):649–656CrossRef
24.
Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Ishibashi T (2002) Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 240(6):423–429CrossRef
25.
Desai TR, Leeper NJ, Hynes KL, Gewertz BL (2002) Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res 104(2):118–123CrossRef
26.
Maruo N, Morita I, Shirao M, Murota S (1992) IL-6 increases endothelial permeability in vitro. Endocrinology 131(2):710–714PubMed
Metadata
Title
Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy
Authors
Liting Hu
Qiulu Chen
Zhaodong Du
Wenying Wang
Guiqiu Zhao
Publication date
01-05-2021
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 5/2021
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-021-01703-6

Other articles of this Issue 5/2021

International Ophthalmology 5/2021 Go to the issue

Original Paper

Clinical features of uveitis in elderly patients in central Tokyo (2013–2018)

Review

Iris clues in ACG

Original Paper

Comparison between sutureless scleral tunnel phacotrabeculectomy with and without placement of anterior capsule remnant

Original Paper

Multimodal ocular evaluation in hemodialysis patients

Original Paper

Quantitative real-time polymerase chain reaction analysis in herpes simplex virus keratitis with and without epithelial involvement

Original Paper

The impact of hemodialysis on retinal and choroidal thickness in patients with chronic renal failure